 | Up a level |
Journal Article
Gaidzik, V., I, Weber, D., Paschka, P., Krieger, S., Kaumanns, A., Kroenke, J., Kapp-Schwoerer, S., Koehne, C-H, Horst, H-A, Schmidt-Wolf, I. G. H., Held, G., Kuendgen, A., Ringhoffer, M., Goetze, K., Kindler, T., Fiedler, W., Wattad, M., Corbacioglu, A., Bullinger, L., Schlegelberger, B., Thol, F., Heuser, M., Ganser, A., Schlenk, R. F., Doehner, H. and Doehner, K. (2015). DNMT3A mutations (DNMT3Amut) in acute myeloid leukemia (AML): monitoring of minimal residual disease (MRD). A study of the AML Study Group (AMLSG). Oncol. Res. Treat., 38. S. 7 - 8. BASEL: KARGER. ISSN 2296-5262
Schlenk, R. F., Paschka, P., Krauter, J., Luebbert, M., Brossart, P., Salih, H. R., Theobald, M., Fiedler, W., Wulf, G., Kirchner, H., Hertenstein, B., Heide, F., Westermann, J., Griesshammer, M., Wattad, M., Goetze, K., Girschikofsky, M., Kuendgen, A., Koller, E., Rudolph, C., Heuser, M., Thol, F., Goehring, G., Teleanu, V, Weber, D., Gaidzik, V., I, Doehner, K., Ganser, A. and Doehner, H. (2015). Clinical outcome in older AML patients not fit for intensive chemotherapy: Results of the population-based AMLSG-BiO (NCT01252485) registry study of the German-Austrian AML study group. Oncol. Res. Treat., 38. S. 121 - 123. BASEL: KARGER. ISSN 2296-5262
Schoensteiner, S., Kirchner, E., Mack, S., Bauder-Missbach, H., Hamel, T., Fuerniss, T., Orth, M., Landwehrmeyer, B., Riester, A., Prokein, A., Erhardt, E., Kunecki, J., Eisenschink, A. M., Pieger, R., Doehner, H. and Schlenk, R. F. (2015). A randomized phase-3 study in patients with chemotherapy-induced sensorimotor polyneuropathy evaluating an integrated program including massage, structured kinesthetic three-dimensional mobilization, physical exercises with or without whole-body vibration training. Oncol. Res. Treat., 38. S. 189 - 190. BASEL: KARGER. ISSN 2296-5262
Stegelmann, F., Bangerter, M., Griesshammer, M., Hebart, H., Heidel, F., Hochhaus, A., Moehle, R., Reiter, A., Scheid, C., Kirschbaum, R., Reim, R., Sutter, U., Doehner, H., Schlenk, R. F. and Doehner, K. (2015). A phase-Ib/II study of ruxolitinib plus pomalidomide in Myelofibrosis: Data from the MPNSG-0212 Trial (NCT01644110). Oncol. Res. Treat., 38. S. 216 - 218. BASEL: KARGER. ISSN 2296-5262
Stegelmann, F., Hebart, H., Bangerter, M., Wolleschak, D., Griesshammer, M., Koschmieder, S., Hochhaus, A., Heidel, F., Moehle, R., Reiter, A., Scheid, C., von Bubnoff, N., Kirschbaum, R., Reim, R., Sutter, U., Vetter, K., Doehner, H., Schlenk, R. F. and Doehner, K. (2016). Ruxolitinib/Pomalidomide combination therapy in myelofibrosis: Current data from the MPNSG-0212 trial. Oncol. Res. Treat., 39. S. 233 - 235. BASEL: KARGER. ISSN 2296-5262